Helsinn closes financing agreement with BancaStato to support business objectives and growth
10 oct. 2023 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
21 sept. 2022 08h34 HE
|
Helsinn Healthcare S.A.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and real-world settings will be presentedHelsinn...
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
08 août 2022 04h07 HE
|
Helsinn Healthcare S.A.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
03 mars 2022 07h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
20 déc. 2021 08h03 HE
|
Helsinn Healthcare S.A.
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)
23 sept. 2020 04h43 HE
|
Helsinn Healthcare S.A.
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) Lugano, Switzerland,...
Helsinn to co-host MF-CTCL satellite symposium alongside Recordati Rare Diseases at the EADV 2019 Congress GNW: European only
09 oct. 2019 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland,...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
19 sept. 2019 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
19 mars 2019 18h00 HE
|
Helsinn Healthcare S.A.
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn...
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
14 févr. 2019 15h22 HE
|
Helsinn Healthcare S.A.
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood...